Literature DB >> 20333877

Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor.

Naim Mitre1, Aida Lteif.   

Abstract

We report the use of anastrozole and bicalutamide in a 5 year-old boy with familial male-limited precocious puberty. Clinical response showed decreased advancement of skeletal maturation, secondary sexual characteristics and aggressiveness with no short-term side effects. The combination seems a better option until long-term data are available.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20333877     DOI: 10.1515/jpem.2009.22.12.1163

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  4 in total

1.  Precocious Puberty in a Boy With Bilateral Leydig Cell Tumors due to a Somatic Gain-of-Function LHCGR Variant.

Authors:  Chelsi Flippo; Vipula Kolli; Melissa Andrew; Seth Berger; Tricia Bhatti; Alison M Boyce; Daniel Casella; Michael T Collins; Emmanuèle Délot; Joseph Devaney; Stephen M Hewitt; Thomas Kolon; Ashwini Mallappa; Perrin C White; Deborah P Merke; Andrew Dauber
Journal:  J Endocr Soc       Date:  2022-08-12

2.  Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.

Authors:  Xin Yuan; Ruimin Chen; Ying Zhang; Xiaohong Yang; Xiangquan Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

3.  A Case of Familial Male-limited Precocious Puberty with a Novel Mutation

Authors:  Shilpa Gurnurkar; Emily DiLillo; Mauri Carakushansky
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-08-06

4.  Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene.

Authors:  Bahar Özcabı; Feride Tahmiscioğlu Bucak; Serdar Ceylaner; Rahşan Özcan; Cenk Büyükünal; Oya Ercan; Beyhan Tüysüz; Olcay Evliyaoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.